Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xantopix AD
- Development stage
- Unknown
- Lead developer
- Synchroline
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Xantopix AD is a topical dermocosmetic product developed by Synchroline (a brand of General Topics s.r.l.) specifically for the management of skin prone to atopic dermatitis. The formulation is designed to address the inflammatory and barrier-deficiency components of eczema. Its primary active ingredient is xanthohumol, a prenylated flavonoid derived from hops (*Humulus lupulus*), which possesses potent anti-inflammatory and antioxidant properties. Xantopix AD aims to reduce erythema, pruritus (itching), and skin irritation by modulating inflammatory mediators and supporting the restoration of the skin's protective lipid barrier. It is typically used as an adjuvant to medical treatments or as a maintenance therapy to prolong periods of remission in patients with atopic dermatitis.
- Brand names
- Xantopix AD
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))IL-6 (Interleukin 6)IL1B (Interleukin-1 beta)
Beyond the preview
Go deeper on Xantopix AD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xantopix AD.